DUSP9 and DUSP12 retards ASK1 phosphorylation, thereby suppressing MAPKs phosphorylation and subsequent inflammation inhibition, consequently ameliorating hepatic steatosis progression28,29. Here, DUSP9 is linked to fatty liver disease.